The National Institute for Health and Care Excellence (NICE) published advice in December 2015 in relation to elosulfase alfa (Vimizim®) for the treatment of patients with mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA). At their meeting on 24 February 2016 AWMSG supported the adoption and implementation of this advice within NHS Wales (refer to the minutes of meetings). The Minister for Health and Social Services has subsequently agreed that the NICE HST advice for elosulfase alfa (Vimizim®) should be implemented within NHS Wales.Refer to HST19: Elosulfase alfa for treating mucopolysaccharidosis type 4A for full guidance on NICE recommendations, including any specific restrictions on the use of the technology.